INOVIO and Advaccine Receive Regulatory Allowance for Two Heterologous Prime-Boost Clinical Trials in China Using INO-4800, INOVIO's COVID-19 DNA Vaccine Candidate
Go back to INOVIO and Advaccine Receive Regulatory Allowance for Two Heterologous Prime-Boost Clinical Trials in China Using INO-4800, INOVIO's COVID-19 DNA Vaccine Candidate| INOVIO PHARMACEUTICALS, Inc. (NASDAQ: INO) | Delayed: 1.25 +0.01 (0.81%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $1.24 | 52 Week High | $11.69 | |||
| Open | $1.24 | 52 Week Low | $4.50 | |||
| Day High | $1.26 | P/E | N/A | |||
| Day Low | $1.22 | EPS | $-0.28 | |||
| Volume | 727,000 | |||||
